The round was led by Coefficient Giving, a philanthropic funder and advisor that partners with donors on cost-effective, high-impact giving across issues such as global health, science R&D and more. Coefficient Giving funding partners have invested a total of $45 million since the company's inception in 2020. Proceeds from the Series A will enable the company to advance its lead program into first-in-human studies in 2026, expand its platform, and build core development capabilities.

VST BIO is a preclinical-stage biotechnology company focused on vascular diseases, e.g., developing first-in-class antibodies targeting edema and inflammation for patients with ischemic stroke. The company's lead candidate, VB-001 has demonstrated efficacy in a number of diseases including stroke, sepsis, and has the potential to reduce cytokine release syndrome in a number of clinical settings.